Last edition
News about "multi-immune modulation"
Japan Approves Sanofi's Wayrilz for Immune Thrombocytopenia
Sanofi’s Wayrilz has been approved in Japan for the treatment of immune thrombocytopenia (ITP). The BTK inhibitor works through multi-immune modulation to address the underlying causes of the disease.
Multi-immune Modulation | 24/06/2026 | By News Bureau
EU Approves Sanofi's Wayrilz as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has received EU approval for Wayrilz, the first Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for immune thrombocytopenia, offering a novel multi-immune modulation approach. The approval is based on positive results from LUNA 3 study, which demonstrated rapid and durable platelet responses.
Multi-immune Modulation | 24/12/2025 | By News Bureau | 192
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy